Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to find the maximum tolerated dose and preliminary efficacy of
desmopressin as an haemostatic agent, when is administered to patients with colorectal cancer
and rectal bleeding, before specific oncologic treatment with surgery and/or chemotherapy
and/or radiotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Laboratorio Elea Phoenix S.A. Laboratorio Elea S.A.C.I.F. y A.